Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (5992)	1/27/1999 8:09:00 AM
From: sam	Read Replies (1) of 6136

Although the deal IMO was not the best "financially" for current AGPH shareholders (based on Tuesday's closing price), I believe one of the major reasons behind the deal was the ability for AGPH to remain essentially autonomous, while getting WLA's cash to continue developing their own products. AGPH now becomes WLA's AIDS division. And they will hold their own (as they already are) very well in that area. The big winner here is clearly WLA. They get AGPH, Viracept, AGPH's pipeline, its drug discovery program (including Alanex), and its winning salesforce for NO significant premium. WLA worked out a great deal (unless there's something we don't know about looming ahead for AGPH). Now they'll be working for AGPH's shareholders, too.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next